Figure 1Diagram and antigenicity evaluation of three recombinant Plasmodium vivax merozoite surface protein 1 (PvMSP1) proteins: rPvMSP1-19, rPvMSP1-33 Sal 1, and rPvMSP1-33 Belem. (A) A diagram of the three recombinant proteins produced. (B) SDS-PAGE of rPvMSP1-19, rPvMSP1-33 Sal 1, and rPvMSP1-33 Belem. Successful expression of these recombinant proteins in Escherichia coli was confirmed using SDS-PAGE and Coomassie blue staining. (C) Western blot analyses of rPvMSP1-19, rPvMSP1-33 Sal 1, and rPvMSP1-33 Belem. Antigenicity and the ability to differentiate specific antibodies against the three recombinant proteins were analyzed via Western blotting with sera obtained from patients infected with PvMSP1-Sal 1 (patient serum-MSP1 Sal 1) and PvMSP1-Belem (patient serum-MSP1 Belem), and sera from healthy individuals (normal serum). Lanes: M, molecular mass marker; 1, rPvMSP1-Belem; 2, rPvMSP1-Sal 1; 3, rPvMSP1-19. SDS-PAGE = sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Figure 2Levels of antibodies specific to Plasmodium vivax merozoite surface protein 1 (PvMSP1)-19, PvMSP1-23 Sal 1, and PvMSP1-23 Belem among malaria patients in vivax endemic regions of Korea. * p < 0.05. OD = optical density.
Table 1Seroprevalence of antibodies specific to Plasmodium vivax merozoite surface protein 1 (PvMSP1)-19, PvMSP1-23 Sal 1, and PvMSP1-23 Belem in 221 samples from a Korean population.
|
PvMSP1-19* |
PvMSP1-23 Sal 1 |
PvMSP1-23 Belem |
Positive, n (%) |
198 (89.6) |
142 (64.3) |
106 (48.0) |
Negative, n (%) |
23 (10.4) |
79 (35.7) |
115 (52.0) |
Table 2Details of the patterns of seropositivity to Plasmodium vivax merozoite surface protein 1 (PvMSP1)-19, PvMSP1-23 Sal 1, and PvMSP1-23 Belem in 221 P. vivax-infected Korean individuals.
|
Case 1 |
Case 2 |
Case 3 |
Case 4 |
Case 5 |
Case 6 |
Case 7 |
Case 8 |
Total |
PvMSP1-19 |
+ |
+ |
+ |
+ |
− |
− |
− |
− |
|
PvMSP1-23 Sal 1 |
+ |
− |
+ |
− |
+ |
+ |
− |
− |
|
PvMSP1-23 Belem |
+ |
− |
− |
+ |
− |
+ |
+ |
− |
|
No. of individuals, n (%) |
100 (45.3) |
53 (24.0) |
39 (17.6) |
6 (2.7) |
3 (1.4) |
0 (0) |
0 (0) |
20 (9.0) |
221 (100) |